InvestorsObserver
×
News Home

Is Mersana Therapeutics Inc (MRSN) a Good Buy in the Biotechnology Industry?

Wednesday, October 18, 2023 10:14 AM | InvestorsObserver Analysts

Mentioned in this article

Is Mersana Therapeutics Inc (MRSN) a Good Buy in the Biotechnology Industry?

Mersana Therapeutics Inc (MRSN) is near the middle in its industry group according to InvestorsObserver. MRSN gets an overall rating of 42. That means it scores higher than 42 percent of stocks. Mersana Therapeutics Inc gets a 49 rank in the Biotechnology industry. Biotechnology is number 70 out of 148 industries.

Overall Score - 42
MRSN has an Overall Score of 42. Find out what this means to you and get the rest of the rankings on MRSN!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Mersana Therapeutics Inc Stock Today?

Mersana Therapeutics Inc (MRSN) stock is trading at $1.50 as of 10:01 AM on Wednesday, Oct 18, a decline of -$0.02, or -1.64% from the previous closing price of $1.52. The stock has traded between $1.40 and $1.53 so far today. Volume today is light. So far 116,861 shares have traded compared to average volume of 2,301,759 shares. Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App